Soligenix (SNGX) Income from Continuing Operations (2010 - 2026)
Soligenix's (SNGX) quarterly Income from Continuing Operations came in at 2884838.0 in Q1 2026, up 10.87% YoY from 2601936.11 in Q1 2025, and up 16.97% on a QoQ basis from 3474606.0 in Q4 2025.
Soligenix (SNGX) Income from Continuing Operations (2010 - 2026) Analysis & Trends
Soligenix (SNGX) has 17 years of Income from Continuing Operations data on file, last reported at 2884838.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 10.87% year-over-year to 2884838.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 11703806.0 (down 17.07% YoY) and the FY2025 annual result came in at 11080380.0, down 34.04% from the prior year.
- Income from Continuing Operations improved to 2884838.0 in Q1 2026, from 3474606.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 1046109.0 in Q1 2023 to a low of 4349021.0 in Q1 2022.
- A 5-year average of 2494140.76 and a median of 2386760.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2023 — Income from Continuing Operations soared 75.95% — and 2024, when it tumbled 86.63%.
- Tracing SNGX's Income from Continuing Operations over 5 years: stood at 3753555.0 in 2022, then jumped by 51.52% to 1819895.0 in 2023, then sank by 86.63% to 3396480.0 in 2024, then declined by 2.3% to 3474606.0 in 2025, then gained by 16.97% to 2884838.0 in 2026.
- The last three Income from Continuing Operations figures came in at 2884838.0 (Q1 2026), 3474606.0 (Q4 2025), and 2580483.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 482.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -782.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 237.01 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 164.49 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -174.37 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -13.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 81.49 Mn |
| 10 | Soligenix | 6.45 Mn | 6.45 Mn | - | -2.05 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.10 Mn |
| Mar 31, 2026 | -2.88 Mn |
| Dec 31, 2025 | -3.47 Mn |
| Sep 30, 2025 | -2.58 Mn |
| Jun 30, 2025 | -2.76 Mn |
| Mar 31, 2025 | -3.24 Mn |
| Dec 31, 2024 | -3.40 Mn |
| Sep 30, 2024 | -1.72 Mn |
| Jun 30, 2024 | -1.64 Mn |
| Mar 31, 2024 | -1.92 Mn |
| Dec 31, 2023 | -1.82 Mn |
| Sep 30, 2023 | -1.66 Mn |
| Jun 30, 2023 | -1.61 Mn |
| Mar 31, 2023 | -1.05 Mn |
| Dec 31, 2022 | -3.75 Mn |
| Sep 30, 2022 | -2.15 Mn |
| Jun 30, 2022 | -2.39 Mn |
| Mar 31, 2022 | -4.35 Mn |
| Dec 31, 2021 | -4.70 Mn |
| Sep 30, 2021 | -2.72 Mn |